Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients.

Christoph Suppan,Daniel Steiner,Eva Valentina Klocker,Florian Posch, Elisabeth Henzinger,Hannah Deborah Müller,Herbert Stöger,Nadia Dandachi,Marija Balic

Breast care (Basel, Switzerland)（2021）

引用 1|浏览6

暂无评分

摘要

In this series of HER2-positive breast cancer patients, the combination of SB3 plus pertuzumab was consistent with the known safety and efficacy profile of trastuzumab and pertuzumab combination.

查看译文

关键词

Breast cancer,Dual inhibition,HER2 positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要